Exploring Three High Growth Tech Stocks in Australia

In This Article:

In the last week, the Australian market has been flat, yet it is up 17% over the past year with earnings forecasted to grow by 12% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and scalability potential in line with these positive market trends.

Top 10 High Growth Tech Companies In Australia

Name

Revenue Growth

Earnings Growth

Growth Rating

Clinuvel Pharmaceuticals

22.32%

27.42%

★★★★★★

Pureprofile

14.94%

80.73%

★★★★★☆

Adherium

86.80%

73.66%

★★★★★★

ImExHS

20.47%

111.20%

★★★★★★

Telix Pharmaceuticals

20.19%

38.31%

★★★★★★

AVA Risk Group

32.56%

118.83%

★★★★★★

Careteq

37.17%

126.21%

★★★★★☆

Pointerra

56.62%

126.45%

★★★★★★

Wrkr

36.31%

100.29%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

Click here to see the full list of 63 stocks from our ASX High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Pro Medicus

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$19.89 billion.

Operations: Pro Medicus generates revenue primarily from producing integrated software applications for the healthcare industry, amounting to A$161.50 million. The company's offerings focus on imaging software and radiology information systems, serving clients in various regions including Australia, North America, and Europe.

Pro Medicus, a standout in the Australian tech landscape, is demonstrating robust growth with earnings projected to increase by 18.9% annually, surpassing the broader market's average of 12.2%. This growth trajectory is bolstered by a significant revenue rise of 17% per year, outpacing the Australian market's 5.5%. The company's commitment to innovation is evident from its R&D spending trends which have consistently aligned with expanding its technological capabilities in healthcare imaging solutions. Recent financial outcomes underscore this momentum; for FY2024, Pro Medicus reported a revenue surge to AUD 166.33 million from AUD 127.33 million in the previous year and an impressive jump in net income to AUD 82.79 million up from AUD 60.65 million. Moreover, Pro Medicus has enhanced shareholder returns through strategic capital management evidenced by a recent dividend hike to 40 cents fully franked—an increase of over one-third compared to last year—reflecting confidence in sustained profitability and cash flow positivity. These financial maneuvers not only highlight their fiscal prudence but also reinforce their stature within high-growth sectors driven by advanced software solutions and client-centric innovations.